肾移植患者的临床排斥反应与持续免疫调节
Clinical rejection and persistent immune regulation in kidney transplant patients.
作者信息
Hendrikx T K, Klepper M, Ijzermans Jan, Weimar W, Baan C C
机构信息
Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
出版信息
Transpl Immunol. 2009 Jul;21(3):129-35. doi: 10.1016/j.trim.2009.04.003. Epub 2009 May 3.
We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation. Kidney recipients (N=15) were randomized to receive either anti-CD25 mAb induction (i.e., daclizumab) or steroids for 4 months. We analyzed the presence and suppressive activity of CD4(+)CD25(high+)FoxP3(+) peripheral T-cells in samples obtained at pre and 4-6 months after transplantation. Anti-CD25 mAb therapy and treatment with steroids did not significantly affect protein expression of FoxP3. However, at the functional level, significant differences were found in the regulatory activities of CD4(+)CD25(high+) T-cells from the anti-CD25 group vs those from the steroid group. At 4-6 months after transplantation, the regulatory activities of CD4(+)CD25(high+) T-cells were comparable to those before anti-CD25 mAb therapy; 49+/-13% (mean+/-SEM) vs 40+/-14% at a 1:20 ratio (CD25(high+):CD25(-/dim)), respectively. In contrast, the regulatory capacities of CD(+)D25(bright+) T-cells from the steroid patient group became significantly impaired. The percentage inhibition of the anti-donor response decreased from 57+/-12% before transplantation to 12+/-7% after transplantation (p<0.01). Five out of 15 patients experienced a rejection episode. At 4-6 months after transplantation, the CD25(high+) cells from these rejectors (who all received daclizumab induction therapy) had clear regulatory function, while suppression by CD25(high+) cells from non-rejectors (N=10) was significantly lower. The percentage inhibition of the anti-donor response was 48+/-14% (mean+/-SEM) vs 10+/-7%, respectively, p=0.02. Anti-CD25 mAb induction therapy does not negatively influence the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from kidney transplant recipients on tacrolimus and MMF. The majority of these patients experienced an acute rejection episode, which suggests that immune activation is required for persistent immunoregulatory function.
我们评估了接受他克莫司和霉酚酸酯(MMF)治疗的患者体内CD4(+)CD25(high+)FoxP3(+) T细胞的调节功能是否受到先前的类固醇和抗CD25单克隆抗体诱导治疗的影响,以及该功能是否与肾移植后的排斥反应相关。肾移植受者(N = 15)被随机分为接受抗CD25单克隆抗体诱导治疗(即达利珠单抗)或类固醇治疗4个月。我们分析了移植前及移植后4 - 6个月获取的样本中CD4(+)CD25(high+)FoxP3(+)外周T细胞的存在情况及其抑制活性。抗CD25单克隆抗体治疗和类固醇治疗对FoxP3的蛋白表达没有显著影响。然而,在功能水平上,抗CD25组与类固醇组的CD4(+)CD25(high+) T细胞的调节活性存在显著差异。移植后4 - 6个月,抗CD25单克隆抗体治疗组的CD4(+)CD25(high+) T细胞的调节活性与治疗前相当;在1:20比例(CD25(high+):CD25(-/dim))下分别为49±13%(平均值±标准误)和40±14%。相比之下,类固醇治疗组患者的CD(+)D25(bright+) T细胞的调节能力显著受损。抗供体反应的抑制百分比从移植前的57±12%降至移植后的12±7%(p < 0.01)。15名患者中有5名经历了排斥反应。移植后4 - 6个月,这些发生排斥反应的患者(均接受达利珠单抗诱导治疗)的CD25(high+)细胞具有明显的调节功能,而非排斥反应患者(N = 10)的CD25(high+)细胞的抑制作用则显著降低。抗供体反应的抑制百分比分别为48±14%(平均值±标准误)和10±7%,p = 0.02。抗CD25单克隆抗体诱导治疗不会对接受他克莫司和MMF治疗的肾移植受者的CD4(+)CD25(high+)FoxP3(+) T细胞的调节功能产生负面影响。这些患者中的大多数经历了急性排斥反应,这表明持续的免疫调节功能需要免疫激活。